Free Trial

Oncternal Therapeutics (ONCT) Insider Trading & Ownership

Oncternal Therapeutics logo
$1.50
+0.04 (+2.74%)
(As of 11/1/2024 ET)

Oncternal Therapeutics (NASDAQ:ONCT) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
11.20%
Number Of
Insiders Buying
(Last 12 Months)
2
Amount Of
Insider Buying
(Last 12 Months)
$92,735.84
Number Of
Insiders Selling
(Last 12 Months)
0
Get ONCT Insider Trade Alerts

Want to know when executives and insiders are buying or selling Oncternal Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

ONCT Insider Buying and Selling by Quarter

Oncternal Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/8/2024Robert James WillsDirectorBuy3,086$8.96$27,650.56  
3/28/2024Robert James WillsDirectorBuy6,914$8.48$58,630.72  
2/23/2024David F HaleDirectorBuy714$9.04$6,454.56  
(Data available from 1/1/2013 forward)

ONCT Insider Trading Activity - Frequently Asked Questions

The list of insiders at Oncternal Therapeutics includes Chase C Leavitt, David F Hale, Gunnar F Kaufmann, James B Breitmeyer, Richard G Vincent, Robert James Wills, and Salim Yazji. Learn more on insiders at ONCT.

11.20% of Oncternal Therapeutics stock is owned by insiders. Learn more on ONCT's insider holdings.

The following insiders have purchased ONCT shares in the last 24 months: Chase C Leavitt ($4,350.00), David F Hale ($6,454.56), Gunnar F Kaufmann ($9,830.00), James B Breitmeyer ($29,000.00), Richard G Vincent ($9,000.00), Robert James Wills ($86,281.28), and Salim Yazji ($4,300.00).

Insiders have purchased a total of 20,114 ONCT shares in the last 24 months for a total of $149,215.84 bought.



This page (NASDAQ:ONCT) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners